$87.40 $1.46 (1.7%)

04:00 PM EDT on 10/18/19

Seattle Genetics, Inc. (NASDAQ:SGEN)

CAPS Rating: 3 out of 5

A biotechnology company, which develops monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.

Current Price $87.40 Mkt Cap $14.9B
Open $86.05 P/E Ratio 0.00
Prev. Close $85.94 Div. (Yield) $0.00 (0.0%)
Daily Range $84.91 - $88.68 Volume 1,327,827
52-Wk Range $54.30 - $88.68 Avg. Daily Vol. 854,402

Caps

How do you think NASDAQ:SGEN will perform against the market?

Add Stock to CAPS Watchlist

All Players

460 Outperform
35 Underperform
 

All-Star Players

92 Outperform
11 Underperform
 

Wall Street

12 Outperform
6 Underperform
 

Top NASDAQ:SGEN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

LifeScientist (31.88)
Submitted March 02, 2016

good dream for sales and appreciation

PDTBiotech (87.48)
Submitted July 07, 2011

$2.34B for a drug which treats HL and ALCL seems very, very rich, even when taking SGEN's strong balance sheet into account. Very cool platform, but the target for brentuximab vedotin is expressed on a narrow enough set of tumor types to keep this… More

NASDAQ:SGEN VS S&P 500 (SPY)

Fools bullish on NASDAQ:SGEN are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about SGEN.

Recs

0
Member Avatar TMFBiologyFool (65.06) Submitted: 10/2/2019 1:46:46 PM : Outperform Start Price: $84.58 NASDAQ:SGEN Score: -0.42

Multiple drugs in late-stage development.

Recs

0
Member Avatar SmoothHughes (91.58) Submitted: 11/17/2018 8:51:07 AM : Outperform Start Price: $56.99 NASDAQ:SGEN Score: +44.14

Technology replaces a 40 year old protocol for fighting certain blood cancers.

Recs

0
Member Avatar Bigsef77 (66.68) Submitted: 10/1/2018 2:51:48 PM : Outperform Start Price: $13.06 NASDAQ:SGEN Score: +410.17

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Business Wire Business Wire•October 1, 2018

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
More
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--

-ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of Care Chemotherapy-

-Statistically Significant Improvement Achieved in All Key Secondary Endpoints, Including Overall Survival-

-First Randomized Phase 3 Trial to Show Improvement in Overall Survival in Frontline Peripheral T-Cell Lymphoma-

-Data to be Presented at the 2018 ASH Annual Meeting; Global Regulatory Submissions Planned-

Seattle Genetics, Inc. (SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. The trial demonstrated a statistically significant improvement in progression-free survival (PFS) of ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone) versus the control arm, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). ECHELON-2 is a global, randomized, double-blind, multicenter trial evaluating ADCETRIS as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), also known as mature T-cell lymphoma (MTCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed on the surface of several types of PTCL. ADCETRIS is currently not approved for the frontline treatment of PTCL.

Leaderboard

Find the members with the highest scoring picks in SGEN.

Score Leader

lloydvon

lloydvon (< 20) Score: +1,707.96

The Score Leader is the player with the highest score across all their picks in SGEN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
lloydvon < 20 8/30/2006 Outperform 1Y $4.48 +1,850.89% +142.94% +1,707.96 1 Comment
Zipsdad < 20 10/4/2006 Outperform 1Y $4.67 +1,771.52% +138.04% +1,633.48 0 Comment
twildstar 94.45 10/11/2006 7/20/2012 Outperform NS $4.93 +1,672.82% +133.39% +1,539.43 0 Comment
vkowalczuk 70.87 10/19/2006 Outperform 1Y $5.10 +1,613.73% +132.16% +1,481.57 1 Comment
RAIDERFAN77 70.02 1/3/2007 7/1/2009 Outperform 1Y $5.27 +1,558.44% +122.52% +1,435.92 0 Comment
SloopJohnB06 54.50 12/26/2006 Outperform 5Y $5.63 +1,452.40% +124.79% +1,327.61 0 Comment
muae1 < 20 12/18/2006 Outperform NS $5.76 +1,417.36% +122.06% +1,295.30 0 Comment
biogirl < 20 1/8/2007 Outperform 3M $6.45 +1,255.25% +125.01% +1,130.24 0 Comment
opveiby 77.57 1/8/2007 Outperform 1Y $6.46 +1,252.94% +124.96% +1,127.98 0 Comment
Turkmenbashi 43.54 1/8/2007 Outperform 3Y $6.59 +1,226.25% +124.24% +1,102.02 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPiperJaff 84.74 7/17/2019 Outperform NS $64.34 +35.84% -0.77% +36.61 0 Comment
TrackSunTrustRH 76.65 6/11/2018 Outperform NS $66.94 +30.56% +7.10% +23.46 0 Comment
TrackBarclaysCap 89.84 10/23/2017 Outperform NS $63.94 +36.69% +15.82% +20.87 0 Comment
TrackJimCramer 86.32 11/19/2015 Underperform 3W $43.98 +98.73% +43.00% -55.73 0 Comment
TrackUBS 89.72 7/9/2014 Outperform NS $36.73 +137.95% +51.59% +86.36 0 Comment
TrackWayneRogers 50.18 3/21/2014 Outperform 3M $50.19 +74.14% +60.16% +13.98 0 Comment
TrackCreditSuiss 88.12 11/13/2012 Outperform NS $23.58 +270.65% +116.82% +153.83 0 Comment
TrackCantorFitz 42.41 11/8/2012 Underperform NS $21.70 +70.65% +44.26% -26.39 10/31/2014 @ $37.03 0 Comment
TrackPiperJaff 84.74 7/2/2012 Underperform NS $24.90 +71.97% +52.84% -19.13 10/30/2015 @ $42.82 0 Comment
TrackJimCramer 86.32 6/5/2012 Outperform 3W $20.86 +110.83% +61.58% +49.26 11/19/2015 @ $43.98 0 Comment
tracksummerstree 83.69 10/5/2011 Underperform NS $19.80 +341.41% +164.80% -176.61 0 Comment
TrackNeedham 90.15 5/6/2011 Outperform NS $16.70 +423.35% +121.00% +302.35 0 Comment
TrackBioLogicEqu < 20 3/9/2011 Underperform NS $14.79 +490.94% +125.21% -365.73 0 Comment
TrackCanaccord 48.58 11/2/2010 Underperform NS $14.34 +509.48% +150.06% -359.43 0 Comment
TrackBreanMurray < 20 11/1/2010 Underperform NS $16.04 +444.89% +150.46% -294.43 0 Comment
trackthinkequity 90.52 9/28/2010 Outperform NS $14.49 +503.17% +160.64% +342.54 0 Comment
trackthinkequity 90.52 8/31/2010 Outperform NS $11.61 +4.05% +7.09% -3.04 9/14/2010 @ $12.08 0 Comment
trackwbbsecuriti < 20 8/4/2010 Underperform NS $12.65 +590.91% +165.01% -425.90 0 Comment
TrackJimCramer 86.32 11/4/2009 Underperform 3W $8.95 +133.13% +23.02% -110.11 6/6/2012 @ $20.87 0 Comment
TrackDeutscheSec 81.67 8/13/2009 Outperform NS $11.25 +676.89% +200.97% +475.92 0 Comment
TrackOppenheimer < 20 10/27/2008 Outperform NS $8.28 +248.67% +66.68% +181.99 9/7/2012 @ $28.87 0 Comment
TrackRBCCapMkts 84.25 3/19/2008 Outperform NS $8.63 +912.75% +131.69% +781.06 0 Comment
TrackMichaelBrus 82.71 2/14/2008 Outperform 1Y $9.35 +834.76% +129.93% +704.83 0 Comment
TrackJPMorgan 86.98 1/28/2008 Outperform NS $9.34 +34.90% -10.84% +45.75 4/30/2010 @ $12.60 0 Comment
TrackFortisBank < 20 9/21/2007 Outperform NS $11.79 -17.64% -29.70% +12.06 10/2/2008 @ $9.71 0 Comment
TrackWMBlair 74.13 8/21/2007 Outperform NS $11.03 +692.38% +116.99% +575.39 0 Comment
TrackCarisandCo 87.09 3/8/2007 Outperform NS $7.40 +13.78% -6.58% +20.37 3/13/2008 @ $8.42 0 Comment
TrackRBCCapMkts 84.25 1/9/2007 Outperform NS $6.61 +94.99% +10.50% +84.49 10/15/2007 @ $12.89 0 Comment
TrackBofASec 91.66 12/12/2006 Outperform NS $6.17 +503.24% +38.15% +465.09 10/1/2014 @ $37.22 0 Comment
TrackNeedham 90.15 10/25/2006 Outperform NS $4.92 +210.16% -3.55% +213.71 3/31/2011 @ $15.26 0 Comment
TrackNextGen < 20 10/6/2006 Outperform NS $4.95 +272.73% +2.37% +270.35 4/17/2012 @ $18.45 0 Comment